Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus

European Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2001, Pages 185-209

  De Ponti, F ^a   Poluzzi, E ^a   Montanaro, N ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adverse drug reactions; Cardiac arrhythmias; QT interval

Indexed keywords

AMANTADINE; ANESTHETIC AGENT; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIMIGRAINE AGENT; CISAPRIDE; CLARITHROMYCIN; CLINDAMYCIN; DILTIAZEM; DOMPERIDONE; ENFLURANE; FAMOTIDINE; FLUCONAZOLE; FOSCARNET; GLIBENCLAMIDE; HALOPERIDOL; LOSARTAN; NEUROLEPTIC AGENT; NICARDIPINE; OCTREOTIDE; ONDANSETRON; OPIATE; SUMATRIPTAN; UNINDEXED DRUG; VASOPRESSIN;

ARTICLE; CLINICAL PRACTICE; DRUG APPROVAL; DRUG EFFECT; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; HEART REPOLARIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ANIMALS; DRUG THERAPY; ELECTROCARDIOGRAPHY; HUMANS; TORSADES DE POINTES;

EID: 0034917323     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100290     Document Type: Article

References (484)

1. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience
2. Cardiatoxic potential and CNS effects of first-generation antihistamines
3. Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes
4. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation
5. Long QT syndromes and torsade de pointes
6. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
7. Drug-induced torsade de pointes: From molecular biology to bedside
8. + channels and drug-acquired long QT syndrome
9. Clarithromycin associated with torsades de pointes
10. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration
11. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole
12. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
13. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
14. Toxicity of Passiflora incarnata L.
15. Adverse drug reactions: Definitions, diagnosis, and management
16. Analysis of potential adverse drug reactions: A case of mistaken identity
17. Images in cardiovascular medicine. Labile repolarization from "cell to bedside"
18. Generalized seizures as the presentation of flecainide toxicity
19. Flecainide: Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia
20. Drug-induced proarrhythmic effects: Assessment of changes in QT interval
21. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing
22. Acquired long QT syndromes and the risk of proarrhythmia
23. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
24. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome
25. The long QT syndromes: Genetic basis and clinical implications
26. Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1
27. Insulin prolongs the QTc interval in humans
28. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?
29. Block of human heart hH1 sodium channels by amitriptyline
30. Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes
31. Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes
32. Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration
33. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development
34. QTc and psychotropic drugs
35. Exposure to non-cardiac QT-prolonging drugs in the community: Comparison among seven countries
36. A structural basis for drug-induced long QT syndrome
37. Proarrhythmia associated with cisapride in children
38. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias
39. Cisapride and proarrhythmia in childhood
40. Allungamento dell'intervallo QT e aritmie ventricolari maligne in corso di trattamento con cisapride. Descrizione di un caso clinico
41. Effects of cisapride on QT interval in children
42. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
43. Effect of cisapride on the QT interval in infants with gastroesophageal reflux
44. Cisapride-induced long QT interval
45. Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson
46. Effects of cisapride on QTc interval in neonates
47. Effect of cisapride on QT interval in patients with end-stage renal disease
48. Effects of cisapride on ventricular repolarization in children
49. Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: Focus on warfarin and cisapride
50. Cisapride poisoning associated with negative T waves
51. Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography
52. Effects of cisapride on QTc interval in term neonates
53. Effects of cisapride on QT interval in infants: A prospective study
54. Cisapride and QTc interval in children
55. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG
56. + channel by the gastrointestinal prokinetic agent cisapride
57. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval
58. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states
59. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres
60. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart
61. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
62. Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring
63. Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia
64. Intestinal prokinesia by two esters of 4-amino-5-chloro-2-methoxybenzoic acid: Involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo
65. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles
66. Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: Potential utility of mexiletine for the treatment of drug-induced long QT syndrome
67. Cardiac arrhythmias during cytotoxic chemotherapy: Role of domperidone
68. Sudden death in cancer patient on high-dose domperidone
69. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders
70. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers
71. Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: Part 2
72. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers
73. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels
74. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults
75. Effects of granisetron with doxorubicin or epirubicin on ECG intervals
76. Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes
77. Electrocardiographic effects of zatosetron and ondansetron, two 5HT3 receptor antagonists, in anesthetized dogs
78. Safety of bepridil: From review of the European data
79. Bépridil: Intérêt du dosage sérique darts la surveillance du traitement
80. + channels IKr and IKs
81. + channels involved in long QT syndromes, are targets for calcium channel blockers
82. + currents, IKr and IKs, in guinea-pig ventricular myocytes
83. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres
84. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels
85. Aritmie ventricolari gravi secondarie a ipopotassiemia indotta dall'indapamide
86. + current, by the diuretic agent indapamide in guinea pig myocytes
87. Polymorphous ventricular tachycardia due to alpha-blockade
88. Clinical cardiac electrophysiological assessment of indoramin
89. Provocative testing and drug response in a patient with the long QT syndrome
90. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline
91. Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome
92. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes
93. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome
94. Electrophysiologic properties of intravenous isradipine in persons with normal sinus node and atrioventricular nodal function
95. A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil
96. Cardiac electrophysiologic properties of intravenous isradipine in patients with sick sinus syndrome
97. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice
98. Isradipine dynamics and pharmacokinetics in the isolated rabbit heart
99. QT prolongation and torsade de pointes ventricular tachycardia produced by ketanserin
100. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin
101. Prolongation of the QT interval by ketanserin
102. Cardiac electrophysiologic effects of intravenous ketanserin in humans
103. Ketanserin inhibits depolarization-activated outward potassium current in rat ventricular myocytes
104. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart
105. Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential
106. Ventricular arrhythmias associated with lidoflazine: Side-effects observed in a randomized trial
107. Torsade de pointes ventricular tahycardia associated with lidoflazine therapy
108. Studies on the possible mechanisms of lidoflazine arrhythmogenicity
109. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure
110. + currents
111. Losartan improves recovery of contraction and inhibits transient inward current in a cellular model of cardiac ischemia and reperfusion
112. Role of sodium in contrast medium-induced polymorphic ventricular tachycardia: Results in a rabbit model of lengthened QT interval
113. Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2
114. Nonlinear kinetics and pharmacologic response to mibefradil
115. Characterization of mibefradil block of the human heart delayed rectifier hKv1.5
116. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate
117. + currents in human atrium and in cells expressing a Kv1.5-type cloned channel
118. Proceedings: Effects of perhexiline on the electrophysiologic activity of mammalian heart
119. Torsades de pointe with prenylamine
120. Basic mechanisms underlying prenylamine-induced 'torsade de pointes': Differences between prenylamine and fendiline due to basic actions of the isomers
121. Analisi delle modificazioni elettrocardiografiche in corso di trattamento con 2-4-7-triamino-6-fenil-pteridina (triamterene)
122. Triamterene inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes
123. The positive inotropic action of triamterene in isolated heart tissues. Its interaction with beta-adrenergic agonists and electrophysiological investigations
124. A case of torsades de pointes probably caused by trimetaphan intoxication
125. Severe ventricular arrhythmia following parenteral administration of vincamine. Predisposing factors in 6 cases
126. Clarithromycin-induced ventricular tachycardia
127. QT prolongation and Torsades de Pointes associated with clarithromycin
128. Clarithromycin-induced prolonged QT syndrome
129. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats
130. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome
131. Ventricular fibrillation due to long QT syndrome probably caused by clindamycin
132. QT interval prolongation and torsades de pointes due to erythromycin lactobionate
133. Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine
134. Erythromycin-induced cardiac toxicity
135. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval
136. A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes. A case report
137. Torsades de pointes induced by erythromycin
138. The effects of erythromycin on the electrocardiogram
139. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature
140. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes
141. Ionic basis of the differential effects of intravenous anesthetics on erythromycin-induced prolongation of ventricular repolarization in the guinea pig heart
142. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome
143. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
144. Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism
145. + channel Kv1.5 by the antibiotic erythromycin
146. Comparative study of the effects of erythromycin and roxithromycin on action potential duration and potassium currents in canine Purkinje fibers and rabbit myocardium
147. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men
148. + channel HERG
149. Comparison of K current antagonistic properties and proarrhythmic consequences of gatifloxacin, grepafloxacin and sparfloxacin
150. The safety profile of the fluoroquinolones
151. Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance
152. Effects of fluoroquinolones on HERG currents
153. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration
154. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin
155. Comparative tolerability of the newer fluoroquinolone antibacterials
156. Risk of torsades de pointes with non-cardiac drugs
157. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
158. Proarrhythmic effects of fluoroquinolone antibacterial agents: In vivo effects as physiologic substrate for torsades
159. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections
160. Moxifloxacin: A safety update from 26 clinical studies
161. Tachycardia associated with moxifloxacin
162. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone
163. QT prolongation due to roxithromycin
164. Commentary-QT prolongation due to roxithromycin
165. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin
166. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin
167. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers
168. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin
169. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers
170. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring
171. QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant
172. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates
173. Long QT syndrome and torsade de pointes in a patient receiving fluconazole
174. A review of the cardiac systemic side-effects of antihistamines: Ebastine
175. Effect of ketoconazole on QTc
176. Blockade of HERG and Kv1.5 by ketoconazole
177. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity
178. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans
179. E.C.G changes during halothane and enflurane anaesthesia for E.N.T. surgery in children
180. Prolongation of the QT interval by volatile anesthetics in chronically instrumented dogs
181. Cardiac electrophysiologic effects of fentanyl and sufentanil in canine cardiac Purkinje fibers
182. Cardiac arrhythmias in children during outpatient general anaesthesia for dentistry: A prospective randomised trial
183. The effects of halothane and sevoflurane on QT dispersion
184. Anaesthesia and the QT interval in humans. The effects of isoflurane and halothane
185. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: Torsades de pointes develops with halothane but not pentobarbital anesthesia
186. + current in rat ventricular myocytes
187. Actions of halothane, isoflurane, and enflurane on the regional action potential characteristics of canine Purkinje fibers
188. Change in QT interval with anesthesia: Should it determine whether to use a narcotic or inhalation agent?
189. Measurement of heart rate and Q-T interval in the conscious mouse
190. 1) and the delayed rectifier (IK) potassium currents in myocardium: Implications for the mechanism of action
191. Long QT and ventricular arrhythmias in transgenic mice expressing the N terminus and first transmembrane segment of a voltage-gated potassium channel
192. Direct electrophysiological actions of pentobarbital at concentrations achieved during general anesthesia
193. Inhibition of a fast inwardly rectifying potassium conductance by barbiturates
194. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome
195. Tale of two (or three or more) cities
196. QT interval, heart rate and arterial pressures using propofol, thiopentone or methohexitone for induction of anaesthesia in children
197. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia
198. The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans
199. La sindrome idiopatica del QT lungo. Variazioni della durata del QTc durante anestesia con propofol
200. Idiopathic prolonged QT interval and QT dispersion: The effects of propofol during implantation of cardioverter-defibrillator
201. Separation of the components of the delayed rectifier potassium current using selective blockers of IKr and IKs in guinea-pig isolated ventricular myocytes
202. Comparative actions of propofol and thiopentone on cell membranes of isolated guinea pig ventricular myocytes
203. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults
204. Prolongation of QT interval in association with the administration of large doses of opiates
205. Prolongation of QT interval during induction of anaesthesia
206. Haemodynamic and catecholamine responses to induction of anaesthesia and tracheal intubation: Comparison between propofol and thiopentone
207. Effect of anaesthesia on the QT interval
208. Ionic mechanisms mediating the differential effects of methohexital and thiopental on action potential duration in guinea pig and rabbit isolated ventricular myocytes
209. Effect of intravenous anesthetics on inward rectifier potassium current in rat and human ventricular myocytes
210. Effects of d1-methadone on the response to physiological transmitters and on several functional parameters of the isolated guinea-pig heart
211. Arrhythmogenic, antiarrhythmic and inotropic properties of opioids. Effects of piritramide, pethidine and morphine compared on heart muscle isolated from rats
212. Amisulpride poisoning: A report on two cases
213. Torsade de Pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: Report of a case
214. Effet arythmogène des antidépresseurs. Mise en évidence par la stimulation ventriculaire programmée
215. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease
216. The heart of psychotropic drug therapy
217. Inhibition of human IsK channels expressed in Xenopus oocytes by calmodulin antagonists
218. Electrocardiographic abnormalities in patients treated with clozapine
219. In vitro electrophysiological detection of iatrogenic arrhythmogenicity
220. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs
221. Droperidol causes a dose-dependent prolongation of the QT interval
222. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction
223. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature
224. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
225. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current
226. Torsade de pointes and low-dose oral haloperidol
227. Haloperidol-induced torsades de pointes
228. Haloperidol-induced torsade de pointes
229. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill
230. Torsades de pointes associated with intravenous haloperidol in critically ill patients
231. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery
232. Torsade de pointes associated with the use of intravenous haloperidol
233. Haloperidol and torsades de pointes
234. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol
235. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose
236. Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes
237. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes
238. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential
239. ECG changes during haloperidol and pimozide treatment of Tourette's disorder
240. Case report: Reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication
241. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
242. Amplification of quinine cardiac effects by the resistance-reversing agent prochlorperazine in falciparum malaria
243. QT interval prolongation associated with quetiapine (Seroquel) overdose
244. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
245. Efficacy, cardiac safety and tolerability of sertindole: A drug surveillance
246. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG
247. Effets arythmogènes du chlorydrate de sultopride: Corrélation clinique et électro-physiologique cellulaire
248. Torsades de pointes lors d'une intoxication par sultopride
249. Suicidal ingestion of thioridazine as a cause of severe impairment of heart rhythm-polymorphic ventricular tachycardia
250. Iatrogenic torsade de pointes induced by thioridazine
251. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
252. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics
253. Thioridazine cardiotoxicity
254. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current
255. Comparison of the electrophysiological effects of two neuroleptics, melperone and thioridazine, on isolated rat atria
256. Thioridazine toxicity: An experimental cardiovascular study of thioridazine and its major metabolites in overdose
257. Tiapride-induced torsade de pointes
258. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
259. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline
260. Amitriptyline-induced Torsade de Pointes. Successful therapy with atrial pacing
261. A child with cardiac arrhythmia and convulsions
262. Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients
263. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline
264. + channel by the antidepressant drug amitriptyline
265. Electrocardiographic and cardiovascular changes in cats and dogs caused by high doses of amitriptyline given as conventional tablets or a sustained release preparation
266. Effects of dothiepin on delayed conduction produced by ventricular arrhythmia in the canine heart after myocardial infarction
267. The effect of tricyclic antidepressant drugs on the heart
268. Cardiovascular effects of zimelidine and tricyclic antidepressants in conscious rats
269. Acute cardiac effects of fluvoxamine and other antidepressants in conscious rabbits
270. Symptoms and signs of severe citalopram overdose
271. Fatal overdose with citalopram
272. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: Successful therapy with a temporary pacemaker
273. Congenital prolongation of Q-T interval: A family study of three generations
274. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents
275. Potential mechanism of desipramine-related sudden death in children
276. Doxepin induced torsade de pointes
277. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder
278. Torsade de pointes après intoxication monomédicamenteuse à la fluoxétine
279. Fluoxetine and ventricular torsade-is there a link?
280. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man
281. + current activation in guinea pig ventricular myocytes
282. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline
283. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose
284. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients
285. Recurrent ventricular fibrillation in mianserin intoxication
286. Massive inversion of the T wave during treatment with mianserin (Athymil)
287. Tricyclic medication in children and the QT interval: Case report and discussion
288. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs
289. EKG-Veränderungen nach Paroxetin
290. Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation
291. QT prolongation and polymorphous ventricular tachycardia associated with trasodone-amiodarone combination
292. Prolonged QT interval after trazodone overdose
293. Torsade de pointes tachycardias induced by overdosage of zimeldine
294. Extrapyramidal signs following zimelidine overdose
295. Effect of artemether on electrocardiogram in severe falciparum malaria
296. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials
297. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
298. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers
299. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine
300. Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs
301. Syncope par torsade de pointe au cours d'un traitement par la chloroquine. Etude de l'electrogramme Hisier et traitment par le verapamil
302. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects
303. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine
304. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome
305. Mechanism of cardiotoxicity of halofantrine
306. Prolonged QT interval with halofantrine
307. Cardiac effects of antimalarial treatment with halofantrine
308. Cardiac effect of halofantrine
309. Cardiac complications of halofantrine: A prospective study of 20 patients
310. Inhibition of HERG potassium channels by the antimalarial agent halofantrine
311. Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetized guinea-pigs
312. Potentiation of halofantrine-induced QTc prolongation by mefloquine: Correlation with blood concentrations of halofantrine
313. Drug alert: Halofantrine
314. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: A double-blind, placebo-controlled trial
315. Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine
316. Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes
317. Quinine pharmacokinetics: Ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria
318. Experience with quinine in falciparum malaria
319. Antiarrhythmic activity of quinine in humans
320. Interaction between corticosteroid and beta-agonist drugs. Biochemical and cardiovascular effects in normal subjects
321. Therapeutic efficacy and equivalence of tablet and syrup formulations of procaterol hydrochloride in childhood asthma
322. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects
323. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: A randomized clinical trial
324. Salmeterol inhaler using a non-chlorinated propellant. HFA134a: Systemic pharmacodynamic activity in healthy volunteers
325. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?
326. Torsade de pointes after astemizole overdose
327. Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval
328. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion
329. Torsade de pointes ventricular tachycardia associated with overdose of astemizole
330. Accidental astemizole overdose in young children
331. Astemizole-induced ventricular arrhythmias: An unexpected cause of convulsions
332. Drug-induced torsades de pointes in one patient with congenital long QT syndrome
333. Combined use of astemizole and ketoconazole resulting in torsade de pointes
334. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs
335. Prolonged Q-T interval following astemizole overdose
336. + channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines
337. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole
338. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine
339. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: Clinical relevance
340. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists
341. Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring
342. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole
343. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome
344. Effects of histamine H1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles
345. Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys
346. The electrocardiographic effects of cetirizine in normal subjects
347. + currents in cardiac cells: Comparison with terfenadine
348. "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts
349. Disparity between the antihistaminic and antiarrhythmic activities of chlorpheniramine and its isomers
350. Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: Successful treatment with sodium bicarbonate
351. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine
352. Electrocardiographic findings in patients with diphenhydramine overdose
353. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine
354. Cardiac actions of antihistamines
355. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US
356. Comparative clinical studies with ebastine: Efficacy and tolerability
357. Cardiac effects of ebastine and other antihistamines in humans
358. Ebastine: An update of its use in allergic disorders
359. + channel family by ebastine
360. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats
361. Inhibitory effects of the antihistamines epinastine, terfenadine, and ebastine on potassium currents in rat ventricular myocytes
362. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes
363. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig
364. Assessing the cardiac safety of ebastine
365. Assessing the cardiac safety of ebastine
366. Effects of H1 antihistamines on animal models of QTc prolongation
367. Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel
368. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats
369. QT lengthening and life-threatening arrhythmias associated with fexofenadine
370. Fexofenadine-induced QT prolongation: A myth or fact?
371. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
372. Cardiovascular safety of fexofenadine HCl
373. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine
374. Mechanism of the cardiotoxic actions of terfenadine
375. Cardiovascular profile of loratadine
376. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations
377. + channels in human heart: Comparison with terfenadine under physiological conditions
378. Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart
379. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine HI receptor antagonist. Second communication: Lack of central nervous system and cardiovascular effects
380. + channels
381. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine
382. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist
383. One-year treatment of chronic urticaria with mizolastine: Efficacy and safety
384. + channels by the novel second-generation antihistamine mizolastine
385. A case of life-threatening ventricular arrhythmias probably due to psychotropic drugs
386. Torsades de pointes occurring in association with terfenadme use
387. Torsades de pointes after treatment with terfenadine and ketoconazole
388. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine
389. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia
390. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scholar electrocardiogram: Distinguishing a drug effect from spontaneous variability
391. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
392. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics
393. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
394. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine
395. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram
396. Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model
397. + channels in guinea pig ventricular myocytes
398. Ks "swap"
399. Regulation of potassium channels by nonsedating antihistamines
400. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers
401. Kr-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha 1-adrenoceptor stimulation
402. Torsade de pointe. Malignant cardiac arrhythmia induced by amantadine poisoning
403. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate
404. Arsenic-induced torsade de pointes
405. Torsade de pointes and T-U wave alternans associated with arsenic poisoning
406. Arsenic-induced atypical ventricular tachycardia
407. Ventricular fibrillation caused by arsenic poisoning
408. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
409. Cardiotoxicity associated with bupropion overdose
410. Torsade de pointes: An unusual manifestation of chloral hydrate poisoning
411. + channels by dexfenfluramine (Redux)
412. Famotidine and acquired long QT syndrome
413. Spike torsade. Possibly caused by a peripheral vasodilator: Fenoxedil
414. QT prolongation in type 2 diabetes mellitus treated with glibenclamide
415. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)
416. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes
417. The effect of acute hyperglycaemia on QTc duration in healthy man
418. Sulfonylureas blockade of neural and cardiac HERG channels
419. Hydroxyzine hydrochloride: Possible adverse cardiac interactions
420. Effects of mitoxantrone on excitation-contraction coupling in guinea pig ventricular myocytes
421. Effects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes
422. Torsades de pointes after intracoronary papaverine
423. QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine
424. Pentamidine-induced torsade de pointes
425. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
426. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity
427. Torsades de pointes associated with antimicrobial therapy for pneumonia
428. A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias arid QTc prolongation in HIV-infected patients
429. Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender
430. The effects of probucol on QT/QS2 relation and systolic time intervals
431. Electrocardiographic effects of probucol. A controlled prospective clinical trial
432. Factors related to QT interval prolongation during probucol treatment
433. Probucol-induced QT prolongation and syncope
434. Prolongation of the QT interval induced by probucol: Demonstration of a method for determining QT interval change induced by a drug
435. Polymorphic ventricular tachycardia induced by intracoronary injection of ioxaglate in a patient with borderline QT prolongation
436. Changes in QTc interval induced with Renografin-76 and Hypaque-76 during coronary arteriography
437. Addition of sodium to the nonionic contrast medium iohexol during coronary angiography in man. Lack of electrocardiographic or hemodynamic effects
438. Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: A double-blind randomized study
439. Clinical superiority of a new nonionic contrast agent (iopamidol) for cardiac angiography
440. The risk of contrast media-induced ventricular fibrillation is low in canine coronary arteriography with ioxilan
441. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension
442. Ritanserin in the treatment of alcohol dependence: A multi-center clinical trial
443. Ritanserin in the treatment of cocaine dependence
444. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current
445. QT prolongation and torsades de pointes after administration of FK506
446. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: A case report
447. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient
448. Sinus arrest during tacrolimus treatment: Was the QT interval prolonged?
449. Sustained QT prolongation induced by tacrolimus in guinea pigs
450. + currents by the immunosuppressant FK-506 in rat ventricle
451. Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs
452. + currents in rat ventricular myocytes
453. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine
454. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood
455. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes
456. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval
457. Torsades de pointes ventricular tachycardia and terodiline
458. Stereoselective cardiotoxic effects of terodiline
459. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence
460. In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium
461. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs
462. Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline
463. Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline
464. + current by therapeutic concentrations of the antispasmodic agent terodiline
465. + current by terodiline
466. + currents and action potentials
467. Torsade de pointes in a patient receiving intravenous vasopressin
468. Ventricular arrhythmia induced by vasopressin: Torsade de pointes related to vasopressin-induced bradycardia
469. + channels expressed in a mammalian cell line
470. + current
471. Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs
472. A comparison of the electrocardiographic cardiotoxic effects of racemic bupivacaine, levobupivacaine, and ropivacaine in anesthetized swine
473. Cocaine abuse: Repolarization abnormalities and ventricular arrhythmias
474. Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram
475. pH-dependent cocaine-induced cardiotoxicity
476. Nicotine depresses the functions of multiple cardiac potassium channels
477. Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning
478. QT interval prolongation associated with anthracycline cardiotoxicity
479. Ventricular repolarization time indexes following anthracycline treatment
480. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma
481. Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia
482. Sudden death of a patient in complete remission after anthracycline therapy for acute lymphoblastic leukemia
483. Experimental models of torsade de pointes
484. + currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes